Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study

Rune Erichsen; Michael A Kelsh; Kelly S Oliner; Karsten B Nielsen; Trine Frøslev; Anne-Vibeke Lænkholm; Mogens Vyberg; John Acquavella; Henrik Toft Sørensen

doi:10.1016/j.annepidem.2016.05.002

Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study

Rune Erichsen, Michael A Kelsh, Kelly S Oliner, Karsten B Nielsen, Trine Frøslev, Anne-Vibeke Lænkholm, Mogens Vyberg, John Acquavella, Henrik Toft Sørensen

Research output: Contribution to journal › Journal article › Research › peer-review

5 Citations (Scopus)

Abstract

PURPOSE: We aimed to investigate the prevalence and prognostic impact of tumor mesenchymal epithelial transition factor (MET) expression in stage IV gastric cancers in a real-world clinical setting because existing evidence is sparse.

METHODS: The study included archived cancer specimens from 103 stage IV gastric cancer patients (2003-2010). We analyzed MET-protein expression by immunohistochemistry (MET-positive if ≥25% of tumor cells showed MET expression). We calculated overall survival using the Kaplan-Meier method and hazard ratios comparing mortality among MET-positive and MET-negative patients using Cox regression adjusted for age, gender, and comorbidity.

RESULTS: We found that 62.1% (95% confidence interval, 52.0-71.5) of patients had MET-positive tumors. Median survival was lower among patients with MET-positive tumors (3.5 months) than among patients with MET-negative tumors (9.6 months), corresponding to an adjusted hazard ratio of 2.2 (95% confidence interval, 1.3-3.7).

CONCLUSIONS: Tumor MET expression is prevalent and has substantial prognostic impact in stage IV gastric cancer patients.

Original language	English
Journal	Annals of Epidemiology
Volume	26
Issue number	7
Pages (from-to)	500-503
Number of pages	4
ISSN	1047-2797
DOIs	https://doi.org/10.1016/j.annepidem.2016.05.002
Publication status	Published - 2016

Access to Document

10.1016/j.annepidem.2016.05.002

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Erichsen, R., Kelsh, M. A., Oliner, K. S., Nielsen, K. B., Frøslev, T., Lænkholm, A-V., Vyberg, M., Acquavella, J., & Sørensen, H. T. (2016). Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study. Annals of Epidemiology, 26(7), 500-503. Advance online publication. https://doi.org/10.1016/j.annepidem.2016.05.002

@article{5c81d821fc604e9ebe1c5fb8f741f702,

title = "Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study",

abstract = "PURPOSE: We aimed to investigate the prevalence and prognostic impact of tumor mesenchymal epithelial transition factor (MET) expression in stage IV gastric cancers in a real-world clinical setting because existing evidence is sparse.METHODS: The study included archived cancer specimens from 103 stage IV gastric cancer patients (2003-2010). We analyzed MET-protein expression by immunohistochemistry (MET-positive if ≥25% of tumor cells showed MET expression). We calculated overall survival using the Kaplan-Meier method and hazard ratios comparing mortality among MET-positive and MET-negative patients using Cox regression adjusted for age, gender, and comorbidity.RESULTS: We found that 62.1% (95% confidence interval, 52.0-71.5) of patients had MET-positive tumors. Median survival was lower among patients with MET-positive tumors (3.5 months) than among patients with MET-negative tumors (9.6 months), corresponding to an adjusted hazard ratio of 2.2 (95% confidence interval, 1.3-3.7).CONCLUSIONS: Tumor MET expression is prevalent and has substantial prognostic impact in stage IV gastric cancer patients.",

author = "Rune Erichsen and Kelsh, {Michael A} and Oliner, {Kelly S} and Nielsen, {Karsten B} and Trine Fr{\o}slev and Anne-Vibeke L{\ae}nkholm and Mogens Vyberg and John Acquavella and S{\o}rensen, {Henrik Toft}",

year = "2016",

doi = "10.1016/j.annepidem.2016.05.002",

language = "English",

volume = "26",

pages = "500--503",

journal = "Annals of Epidemiology",

issn = "1047-2797",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Prognostic impact of tumor MET expression among patients with stage IV gastric cancer

T2 - a Danish cohort study

AU - Erichsen, Rune

AU - Kelsh, Michael A

AU - Oliner, Kelly S

AU - Nielsen, Karsten B

AU - Frøslev, Trine

AU - Lænkholm, Anne-Vibeke

AU - Vyberg, Mogens

AU - Acquavella, John

AU - Sørensen, Henrik Toft

PY - 2016

Y1 - 2016

N2 - PURPOSE: We aimed to investigate the prevalence and prognostic impact of tumor mesenchymal epithelial transition factor (MET) expression in stage IV gastric cancers in a real-world clinical setting because existing evidence is sparse.METHODS: The study included archived cancer specimens from 103 stage IV gastric cancer patients (2003-2010). We analyzed MET-protein expression by immunohistochemistry (MET-positive if ≥25% of tumor cells showed MET expression). We calculated overall survival using the Kaplan-Meier method and hazard ratios comparing mortality among MET-positive and MET-negative patients using Cox regression adjusted for age, gender, and comorbidity.RESULTS: We found that 62.1% (95% confidence interval, 52.0-71.5) of patients had MET-positive tumors. Median survival was lower among patients with MET-positive tumors (3.5 months) than among patients with MET-negative tumors (9.6 months), corresponding to an adjusted hazard ratio of 2.2 (95% confidence interval, 1.3-3.7).CONCLUSIONS: Tumor MET expression is prevalent and has substantial prognostic impact in stage IV gastric cancer patients.

AB - PURPOSE: We aimed to investigate the prevalence and prognostic impact of tumor mesenchymal epithelial transition factor (MET) expression in stage IV gastric cancers in a real-world clinical setting because existing evidence is sparse.METHODS: The study included archived cancer specimens from 103 stage IV gastric cancer patients (2003-2010). We analyzed MET-protein expression by immunohistochemistry (MET-positive if ≥25% of tumor cells showed MET expression). We calculated overall survival using the Kaplan-Meier method and hazard ratios comparing mortality among MET-positive and MET-negative patients using Cox regression adjusted for age, gender, and comorbidity.RESULTS: We found that 62.1% (95% confidence interval, 52.0-71.5) of patients had MET-positive tumors. Median survival was lower among patients with MET-positive tumors (3.5 months) than among patients with MET-negative tumors (9.6 months), corresponding to an adjusted hazard ratio of 2.2 (95% confidence interval, 1.3-3.7).CONCLUSIONS: Tumor MET expression is prevalent and has substantial prognostic impact in stage IV gastric cancer patients.

U2 - 10.1016/j.annepidem.2016.05.002

DO - 10.1016/j.annepidem.2016.05.002

M3 - Journal article

C2 - 27318530

SN - 1047-2797

VL - 26

SP - 500

EP - 503

JO - Annals of Epidemiology

JF - Annals of Epidemiology

IS - 7

ER -

Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study

Abstract

Access to Document

AUB Link

Fingerprint

Cite this